Literature DB >> 7638083

Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomas.

S Vesalainen1, P Lipponen, M Talja, J Kasurinen, K Syrjänen.   

Abstract

A series of 325 patients with prostatic adenocarcinoma followed-up for over 13 years was subjected to histomorphometric analysis for the following prognostic factors: the Gleason score and 10 nuclear morphometric factors (mean nuclear area, nuclear perimeter, shortest and longest nuclear axis, form factor and their SDs), using the IBAS 1&2 image analyzer. Nuclear factors, Gleason score (P = 0.0013-0.0148), and T-category (P = 0.004-0.0107) were significantly interrelated, while the M-category was independent of the morphometric parameters. Nuclear factors (P = 0.0003-0.5), Gleason score (P < 0.0001), T-category (P < 0.0001) and M-category (P < 0.0001) predicted the disease outcome. In T1-2M0 tumors, the T-category (P = 0.0001), Gleason score (P < 0.0001), SD of nuclear area (P = 0.057), SD of nuclear perimetry (P = 0.039), mean shortest nuclear axis (P = 0.030), SD of the shortest nuclear axis (P = 0.0045), SD of the longest nuclear axis (P = 0.009), and nuclear form factor (P = 0.0123) were significant prognostic factors. In the multivariate survival analysis, the nuclear area had independent prognostic significance only in T1 tumors, whereas in other subcategories, the clinical stage, Gleason score, and patient age included all the available prognostic information. The results indicate that nuclear morphometric measurements are of borderline significance only in evaluating the intrinsic malignancy of prostatic adenocarcinoma.

Entities:  

Mesh:

Year:  1995        PMID: 7638083     DOI: 10.1002/pros.2990270208

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.

Authors:  Jie-Fu Chen; Hao Ho; Jake Lichterman; Yi-Tsung Lu; Yang Zhang; Mitch A Garcia; Shang-Fu Chen; An-Jou Liang; Elisabeth Hodara; Haiyen E Zhau; Shuang Hou; Rafi S Ahmed; Daniel J Luthringer; Jiaoti Huang; Ker-Chau Li; Leland W K Chung; Zunfu Ke; Hsian-Rong Tseng; Edwin M Posadas
Journal:  Cancer       Date:  2015-05-14       Impact factor: 6.860

2.  Prostate cancer: serum and tissue markers.

Authors:  G J Miller; M K Brawer; W A Sakr; J B Thrasher; R Townsend
Journal:  Rev Urol       Date:  2001

3.  Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.

Authors:  Jason Gee; Howard Bailey; Kyungmann Kim; Jill Kolesar; Tom Havighurst; Kendra D Tutsch; William See; Michael B Cohen; Nick Street; Leon Levan; David Jarrard; George Wilding
Journal:  Prostate       Date:  2013-01-17       Impact factor: 4.104

4.  Prognostic factors in prostate cancer.

Authors:  A Buhmeida; S Pyrhönen; M Laato; Y Collan
Journal:  Diagn Pathol       Date:  2006-04-03       Impact factor: 2.644

5.  An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements.

Authors:  Sabrina Campelo; Massimo Valerio; Hashim U Ahmed; Yipeng Hu; Sara L Arena; Robert E Neal; Mark Emberton; Christopher B Arena
Journal:  APL Bioeng       Date:  2017-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.